[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,178,436
  • Shares Outstanding, K 100,550
  • Annual Sales, $ 2,861 M
  • Annual Income, $ 478,600 K
  • EBIT $ 789 M
  • EBITDA $ 806 M
  • 60-Month Beta 0.39
  • Price/Sales 6.43
  • Price/Cash Flow 36.48
  • Price/Book 5.40

Options Overview Details

View History
  • Implied Volatility 43.19% (+0.86%)
  • Historical Volatility 27.75%
  • IV Percentile 88%
  • IV Rank 72.00%
  • IV High 51.29% on 04/16/26
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 22) 7.48 (4.03%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 431
  • Volume Avg (30-Day) 236
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 12,723
  • Open Int (30-Day) 12,111
  • Expected Range 178.02 to 192.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.88
  • Number of Estimates 7
  • High Estimate $2.64
  • Low Estimate $1.47
  • Prior Year $1.06
  • Growth Rate Est. (year over year) +77.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.91 +11.81%
on 07/01/26
186.12 -0.33%
on 07/30/26
+16.96 (+10.07%)
since 06/30/26
3-Month
129.86 +42.85%
on 05/01/26
186.12 -0.33%
on 07/30/26
+53.83 (+40.88%)
since 04/30/26
52-Week
122.14 +51.88%
on 02/12/26
186.12 -0.33%
on 07/30/26
+48.74 (+35.64%)
since 07/30/25

Most Recent Stories

More News
Neurocrine: Q2 Earnings Snapshot

Neurocrine: Q2 Earnings Snapshot

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences: Analyst Conviction Meets the Reality of Medicare Pricing Headwinds

Barchart Research What to Expect from NBIX Earnings NBIX Generated July 29, 2026 Current Price $180.79 EPS Estimate $$1.88 Consensus Rating Strong Buy Average Move 7.75% Neurocrine Biosciences: Analyst...

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

SAN DIEGO , July 23, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team...

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

SAN DIEGO , July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's...

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Thursday, July 30

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

SAN DIEGO , July 1, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont...

NBIX : 185.50 (+2.61%)
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

SAN DIEGO , June 15, 2026 /PRNewswire/ -- Soleno Therapeutics , a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment...

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

SAN DIEGO , June 15, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients...

NBIX : 185.50 (+2.61%)
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

SAN DIEGO , June 15, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst ® Pediatric study showing positive growth...

NBIX : 185.50 (+2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 198.40
2nd Resistance Point 192.26
1st Resistance Point 188.88
Last Price 185.50
1st Support Level 179.36
2nd Support Level 173.22
3rd Support Level 169.84

See More

52-Week High 186.12
Last Price 185.50
Fibonacci 61.8% 161.68
Fibonacci 50% 154.13
Fibonacci 38.2% 146.58
52-Week Low 122.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.